Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...

"Good" (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Parapapillary outer temporal retina thickening can reveal diabetic retinopathy development in children with type 1 diabetes mellitus.

As a retina specialist, one of the most important aspects of eye care I focus on is the prevention and treatment of diabetic retinopathy. This condition is a leading cause of blindness in adults, yet ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Three experts discuss the increased mortality risk for patients with diabetic retinopathy, available screening tools, and ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...